Arena Pharmaceuticals, Inc.’s sphingosine 1-phosphate (S1P) receptor modulator etrasimod did not meet the primary endpoint in the Phase IIb ADVISE clinical trial but the company said its review of data from moderate-to-severe atopic dermatitis patients with uninterrupted courses of treatment show a significant benefit that justifies moving the drug into Phase III testing in the skin disease.
San Diego-based Arena discussed top-line data from ADVISE during a conference call after the stock market closed on 9 November,...







![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)